IBIO Archives - Page 4 of 8

Developments

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

In a major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming protein expression system, iBio (NYSE American:IBIO) is adding three anti-cancer targets to its pipeline of...

July 9, 2021

Executive Moves

iBio adds veteran biopharmaceutical executive Evert Schimmelpennink to board

Evert Schimmelpennink iBio (NYSEA:IBIO) appointed Evert (Eef) Schimmelpennink to its board of directors, effective immediately. In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has...

June 10, 2021

Developments

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...

May 7, 2021

Developments

iBio and Fraunhofer USA conclude litigation and enter license agreement

iBio (NYSE American:IBIO) successfully resolved its lawsuit with Fraunhofer USA, confirming iBio’s ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the...

May 5, 2021

Executive Moves

iBio appoints accomplished financial executive Robert Lutz as CFBO

Robert Lutz iBio (NYSE American:iBio) appointed Robert Lutz as chief financial and business officer (CFBO), effective March 4, 2021. Mr. Lutz will lead iBio’s finance organization and be responsible for building strong...

February 16, 2021

Markets

Cantor Fitzgerald starts iBio at OW; PT $3

Cantor Fitzgerald launched coverage of iBio (NYSE American:IBIO) with an “overweight” rating and price target of $3. The stock closed at $1.46 on Jan. 21. iBio focuses on plant-made biologics manufacturing, which is...

January 22, 2021

Developments

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

iBio’s (NYSE American:IBIO) plant-based FastPharming System and customized FastGlycaneering tools were featured in an article in Genetic Engineering & Biotechnology. Sylvain Marcel, Ph.D., VP of protein expression...

January 11, 2021

Executive Moves

iBio names renowned drug discovery and development expert Martin Brenner as CSO

Martin Brenner iBio (NYSE American:IBIO) appointed Martin Brenner, Doctor of Veterinary Medicine, Ph.D., as chief scientific officer, effective Jan. 18, 2021. Dr. Brenner has a strong history of success heading drug...

December 28, 2020

Developments

iBio to produce atbtherapeutics’ bioengineered antibody-toxin fusion proteins

iBio (NYSE AMERICAN:IBIO) will use its FastPharming System to produce Belgium-based atbtherapeutics’ bioengineered antibody-toxin fusion proteins. The fusion proteins, called atbodies, are being designed for the...

December 1, 2020

Developments

iBio receives U.S. patent for endostatin peptides for the treatment of fibrosis

iBio (NYSE AMERICAN:IBIO) received a patent from the U.S. Patent and Trademark Office, covering a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming System...

November 24, 2020

Tag - IBIO

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

iBio adds veteran biopharmaceutical executive Evert Schimmelpennink to board

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio and Fraunhofer USA conclude litigation and enter license agreement

iBio appoints accomplished financial executive Robert Lutz as CFBO

Cantor Fitzgerald starts iBio at OW; PT $3

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

iBio names renowned drug discovery and development expert Martin Brenner as CSO

iBio to produce atbtherapeutics’ bioengineered antibody-toxin fusion proteins

iBio receives U.S. patent for endostatin peptides for the treatment of fibrosis

General

More